In addition to breast cancer, HER2 status testing is also applied in gastric cancers as trastuzumab is similarly effective in prolonging survival in HER2 positive carcinoma of the gastric and of the gastroesophageal junction2,11. Here, ERBB2 is linked to breast cancer.